Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Arcus Biosciences Inc. | Domvanalimab (AB154) + Zimberelimab (AB122) - (ARC-7) | Non-small cell lung cancer (NSCLC) | Phase 2 | Ongoing | Intravenous | Oncology |
| Arcus Biosciences Inc. | Domvanalimab + zimberelimab vs. zimberelimab vs. chemotherapy - (ARC-10) | Non Small Cell Lung Cancer (NSCLC) | Phase 3 | Trial Discontinued | Intravenous | Oncology |
| Arcus Biosciences Inc. | Domvanalimab (AB154) and IMFINZI (Durvalumab) - (PACIFIC-8) | Non-small cell lung cancer (NSCLC) | Phase 3 | Ongoing | Intravenous | Oncology |
| Arcus Biosciences Inc. | Quemliclustat (AB680) - (PRISM-1) | Untreated metastatic pancreatic ductal adenocarcinoma (mPDAC) | Phase 3 | Enrollment Conclusion | Intravenous | Oncology |
| Arcus Biosciences Inc. | Quemliclustat, domvanalimab, zimberelimab, and chemotherapy (ARC-21) - (STAR-221) | Locally advanced unresectable or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma | Phase 3 | Trial Discontinued | Intravenous | Oncology |
| Arcutis Biotherapeutics Inc. | ARQ-252 | Chronic Hand Eczema | Phase 2b | Trial Completed | Topical | #N/A |
| Arcutis Biotherapeutics Inc. | Roflumilast Cream (ARQ-151) - (DERMIS-1) | Plaque psoriasis | Phase 3 | Data Released | Topical | Immunology: Anti-TNF |
| Arcutis Biotherapeutics Inc. | Roflumilast Cream (ARQ-151) - (DERMIS-1) | Plaque psoriasis | Phase 3 | Data Released | Topical | Immunology: Anti-TNF |
